Back
Articles
06/29/2023

Extramedullary disease in multiple myeloma: a systematic literature review - Blood Cancer J. 2022

Joan Bladé, Meral Beksac, Jo Caers, Artur Jurczyszyn, Marie von Lilienfeld-Toal, Philippe Moreau, Leo Rasche, Laura Rosiñol, Saad Z Usmani, Elena Zamagni, Paul Richardson

Blood Cancer J. 12, 45 (2022). DOI: 10.1038/s41408-022-00643-3. PMID: 35314675; PMCID: PMC8938478.
decoration

Extramedullary disease in multiple myeloma: a systematic literature review

Extramedullary disease (EMD) represents an aggressive form of multiple myeloma (MM), characterized by the ability of a clone and/or subclone to thrive and grow independent of the bone marrow microenvironment. This review is based on a systematic literature search, and will focus on hematogenous EMD, including that with central nervous system (CNS) involvement. Areas covered are incidence, sites of occurrence, prognosis, and treatment outcomes.

Access the Publication

Download

More articles

View all articles
Articles
06/29/2023

Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure! - Journal of Clinical Oncology, 2022

Articles
06/08/2023

Mass spectrometry for the evaluation of monoclonal proteins in MM and related disorders - Blood Cancer J. 2021

Articles
06/29/2023

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma - Front Oncol. 2020

Articles
06/29/2023

Making clinical decisions based on measurable residual disease improves the outcome in Multiple Myeloma - J Hematol Oncol. 2021

Articles
06/29/2023

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications - Front Oncol. 2022

Articles
06/29/2023

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration - Clin Cancer Res. 2021

Articles
08/28/2023

Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma - Blood Adv. 2020

Articles
06/29/2023

IMWG consensus criteria for response and minimal residual disease assessment in Multiple Myeloma - Lancet Oncol. 2016

Articles
08/28/2023

Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma - Cancers 2021